Get the content you want anytime you want.
The Best Infectious Disease News Delivered Weekly

The Contagion® HCV / Hepatitis specialty page provides HCV / hepatitis-specific clinical news and articles, coverage from conferences and meetings, links to condition-specific resources, and videos and other content.


Egyptian Initiative Aims to Create “A World Free of Hepatitis C”
According to Tour n’ Cure, an Egyptian initiative that aims to rid the world of hepatitis C, Egypt aims to give program participants an opportunity to receive full treatment at an extremely low cost, while touring “the land that gave birth to the first great civilization.”
NSF Grant Funds Research to Better Predict Infectious Disease Outbreaks
Penn State researchers have been granted $2.35 million to go towards finding a way of better predicting infectious disease outbreaks.
Evaluating the Use of Anticoagulants in Patients with Advanced Liver Disease
Should practitioners administer these drugs to patients with advanced liver disease, despite the risks?
Top 5 <i>Contagion</i>® News Articles for the Week of February 26, 2017
Did you read this week’s top infectious disease news coverage from Contagion®?
Merck Loses Big Money on HCV Drug
Kenilworth, New Jersey-based Merck, will take a loss of $0.22 a share from last year’s fourth quarter. This will account for a total loss of $2.9 billion, or $1.9 billion after taxes. The pharmaceutical giant had previously reported a profit of $0.42 a share for that period.
Research Finds HCV Infection Can Affect More than Liver
It is becoming increasingly clear that the hepatitis C virus (HCV) can wreak havoc on a patient’s psychological well-being, even in the absence of a continued viral presence.
The Missing Link in Eliminating Viral Hepatitis B & C
Elimination of viral hepatitis depends on individuals actively participating in their own healthcare and management. They can only do this if they understand why and how to protect their miraculous, life-sustaining liver from harm. Education is the key to prevention.
Does Race or Ethnicity Impact the Efficacy of DAAs for the Treatment of HCV?
Researchers recently examined data from 21k+ patients in the Veterans Affairs healthcare system to determine if a correlation exists between race or ethnicity and the efficacy of direct-acting antiviral (DAAs) for the treatment of hepatitis C (HCV).
The new test can differentiate between Lyme disease and 7 other tick-borne diseases.